Proteins





MK-8189

Cat. No.: HY-153093 CAS No.: 1424371-93-6 Molecular Formula: $C_{_{19}}H_{_{22}}N_{_{6}}OS$ Molecular Weight: 382.48

Target: Phosphodiesterase (PDE) Pathway: Metabolic Enzyme/Protease Storage: Powder -20°C 3 years In solvent -80°C 6 months

> -20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 125 mg/mL (326.81 mM; Need ultrasonic)

| Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg |
|------------------------------|-------------------------------|-----------|------------|------------|
| | 1 mM | 2.6145 mL | 13.0726 mL | 26.1452 mL |
| | 5 mM | 0.5229 mL | 2.6145 mL | 5.2290 mL |
| | 10 mM | 0.2615 mL | 1.3073 mL | 2.6145 mL |

Please refer to the solubility information to select the appropriate solvent.

| _ | - | \sim | $\mathbf{I} \sim \mathbf{A}$ | L ACTI | |
|---|---|--------|------------------------------|--------|--|
| | | | | | |
| | | | | | |

| Description | MK-8189 is a potent, orally active and selective PDE10A inhibitor with a K _i value of 29 pM. MK-8189 can be used in research of schizophrenia ^[1] . |
|---------------------------|---|
| IC ₅₀ & Target | PDE10A 29 pM (Ki) |

In Vivo MK-8189 (0.25-0.75 mg/kg; po) attenuates rats' locomotor activity in a dose-dependent manner^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| Animal Model: | Male Wistar-Hannover rats ^[1] |
|-----------------|---|
| Dosage: | 0.25, 0.5, and 0.75 mg/kg |
| Administration: | Oral administration |
| Result: | Improved identification ability relative to the vector handling animal. |

| Caution: Product has not been fully validated for medical applications. For research use only. Tel: 509-228-8998 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA | REFERENCES |
|---|---|
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | [1]. Layton ME, et, al. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia. J Med Chem. 2023 Jan 26;66(2):1157-1171. |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | |
| Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com | Caution: Product has not been fully validated for medical applications. For research use only |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

Page 2 of 2 www.MedChemExpress.com